334 related articles for article (PubMed ID: 12844139)
1. Pharmacokinetics of anakinra in subjects with different levels of renal function.
Yang BB; Baughman S; Sullivan JT
Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
4. Garenoxacin pharmacokinetics in subjects with renal impairment.
Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.
Teichert J; Tuemmers T; Achenbach H; Preiss C; Hermann R; Ruus P; Preiss R
J Clin Pharmacol; 2005 Mar; 45(3):313-28. PubMed ID: 15703366
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of dexrazoxane in subjects with impaired kidney function.
Brier ME; Gaylor SK; McGovren JP; Glue P; Fang A; Aronoff GR
J Clin Pharmacol; 2011 May; 51(5):731-8. PubMed ID: 20484616
[TBL] [Abstract][Full Text] [Related]
9. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
[TBL] [Abstract][Full Text] [Related]
10. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.
Courtney R; Sansone A; Smith W; Marbury T; Statkevich P; Martinho M; Laughlin M; Swan S
J Clin Pharmacol; 2005 Feb; 45(2):185-92. PubMed ID: 15647411
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
12. Effects of renal function on recainam pharmacokinetics and pharmacodynamics.
Cheng JW; Charland SL; Goldfarb S; Spinler SA
Clin Pharmacol Ther; 1995 May; 57(5):492-8. PubMed ID: 7768071
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of vitamin E metabolites in the blood of renal failure patients.
Galli F; Floridi AG; Floridi A; Buoncristiani U
Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
[TBL] [Abstract][Full Text] [Related]
14. The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease.
Yan JH; Ataga K; Kaul S; Olson JS; Grasela DM; Gothelf S; Kutlar A; Orringer E
J Clin Pharmacol; 2005 Apr; 45(4):434-45. PubMed ID: 15778424
[TBL] [Abstract][Full Text] [Related]
15. Bromfenac disposition in patients with impaired kidney function.
Ermer JC; Boni JP; Cevallos WH; DeCleene S; Burghart P; Rudnick MR; Fruncillo RJ; Berns JS; Cohen RM
Clin Pharmacol Ther; 1997 Mar; 61(3):312-8. PubMed ID: 9084456
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
Zhou XJ; Swan S; Smith WB; Marbury TC; Dubuc-Patrick G; Chao GC; Brown NA
Antimicrob Agents Chemother; 2007 Dec; 51(12):4231-5. PubMed ID: 17875994
[TBL] [Abstract][Full Text] [Related]
18. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.
Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA
Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of pilocarpine in subjects with varying degrees of renal function.
St Peter JV; Lambrecht LJ; Gunderson BW; Andersen SA; Gallagher SC; Swan SK
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1470-5. PubMed ID: 11185668
[TBL] [Abstract][Full Text] [Related]
20. Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril.
Bevan EG; McInnes GT; Aldigier JC; Conte JJ; Grunfeld JP; Harper SJ; Meyer BH; Pauly N; Wilkinson R
Br J Clin Pharmacol; 1993 Feb; 35(2):128-35. PubMed ID: 8443030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]